Roche, Epizyme Form Immunotherapy PactBy
Epizyme, a clinical-stage biopharmaceutical company creating epigenetic therapies for people with cancer, has entered into a collaboration agreement with Genentech, a member of the Roche Group, to conduct a clinical trial to investigate the anti-cancer effects of Epizyme’s EZH2 inhibitor, tazemetostat, and Genentech’s recently approved anti-PD-L1 cancer immunotherapy, Tecentriq (atezolizumab), when used in combination. The study will evaluate this combination regimen for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), the most common form of non-Hodgkin lymphoma.
Under the agreement, Genentech will manage study operations for the planned clinical trial. The planned phase Ib clinical trial is expected to begin enrolling patients in the second half of 2016.